Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan
Autor: | Norifumi Tsukamoto, Atsushi Isoda, Shigeki Ito, Akio Saito, Toshihide Kawamura, Hideto Tamura, Kayoko Murayama, Morio Matsumoto, Yutaka Tsukune, Tomomi Miyanaga, Keiichi Moriya, Tohru Sakura, Sakae Tanosaki, Hirokazu Murakami, Hirotaka Nakahashi, Hiroshi Handa, Makoto Sasaki, Akihiko Yokohama, Akihiro Ohtsu, Naoya Nakamura, Masaru Kojima, Michiaki Koike |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Pleural effusion Population Asymptomatic Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Japan Internal medicine medicine Humans education Survival rate Aged Retrospective Studies Aged 80 and over education.field_of_study business.industry Waldenstrom macroglobulinemia Macroglobulinemia Retrospective cohort study Hematology Middle Aged medicine.disease Surgery Survival Rate 030220 oncology & carcinogenesis Rituximab Female medicine.symptom Waldenstrom Macroglobulinemia business 030215 immunology medicine.drug |
Zdroj: | International journal of hematology. 106(5) |
ISSN: | 1865-3774 |
Popis: | Although population-based cancer registries have reported lower incidence of Waldenstrӧm macroglobulinemia (WM) in East Asia than in Western countries, previous retrospective analyses have found the clinical features of WM to be similar in these two populations. To clarify the characteristics of Japanese WM patients, we retrospectively analyzed clinical and laboratory characteristics, treatments, outcomes, and prognostic factors in 93 patients with WM. Based on the Second International Workshop on WM (IWWM-2) criteria, symptomatic WM was found in 73 (78.5%) and asymptomatic WM in 20 (21.5%) of cases examined. The median overall survival (OS) was similar to that in reports from Western countries. Patients receiving treatment regimens including rituximab exhibited significantly better survival than those not given rituximab. Although prognostic factors for WM in Western countries may not apply to Japanese patients, our finding that newly diagnosed WM patients with pleural effusion have a poorer prognosis suggests that this may be a novel predictor of adverse prognosis in symptomatic WM. |
Databáze: | OpenAIRE |
Externí odkaz: |